Meet Alexander Seyf

Alexander is CEO of Autolomous, a digital technology company focused on cell and gene therapy manufacturing and supply chain orchestration. Through platforms such as AutoloMATE, the company supports electronic batch records, workflow management, traceability, quality oversight, and data integration for complex advanced therapy processes.

His work addresses one of the less visible but critical challenges in CGT: the persistence of paper-heavy, manual, and fragmented systems in a field where every batch may be linked to an individual patient. Alexander has become a prominent advocate for digital infrastructure as a prerequisite for scale, compliance, and patient safety. Alongside Autolomous, he founded Act for Hope, a foundation intended to support collaboration and strengthen the wider cancer and advanced therapies ecosystem.

“I disagree with the idea that CGT manufacturing will always need to remain highly artisanal because the therapies themselves are biologically complex. Complexity doesn’t automatically mean scalability is impossible. We absolutely can industrialize these processes, but it requires purpose-built digital infrastructure rather than trying to force traditional pharma manufacturing models onto advanced therapies.”